The use of pictograms improves symptom evaluation by patients with functional dyspepsia.

Abstract:

BACKGROUND:No validated patient-reported outcome (PRO) measure exists for functional dyspepsia (FD) assessment. Verbal descriptions of different upper abdominal symptoms may be poorly distinguishable to patients. AIM:To investigate whether understanding of FD symptoms is enhanced by pictograms symbolising the nature of the symptoms, besides verbal descriptors. METHODS:Consecutive FD patients were randomised to fill out a questionnaire assessing nineupper gastrointestinal symptoms (post-prandial fullness, early satiation, epigastric pain, epigastric burning, bloating centred in the upper abdomen, nausea, vomiting, heartburn, regurgitation) with or without accompanying pictograms. Symptoms were rated for frequency and severity (0-5), and patients also identified the most bothersome symptom. Subsequently, in-depth history was taken by an expert clinician, who filled out the same symptom ratings. Concordance between patient and clinician ratings was quantified using chi-square and kappa statistics. RESULTS:Content validity of pictograms was first confirmed by 15 FD patients. Next, 76 patients (52 women, age 42.2 ± 1.9) were randomised to questionnaires with or without pictograms. The concordance with clinician's assessment as gold standard rose from 36 without to 48% for questions with pictograms (P < 0.0001). Considering the Rome III subdivision, benefit in concordance with pictograms was present for post-prandial distress, epigastric pain syndrome and reflux symptoms. Kappa statistics confirmed these gains (weighted kappa values for concordance of symptom frequency ratings rose from 0.214 to 0.446 with pictograms), and also showed better concordance of the most bothersome symptom with pictograms. CONCLUSION:Pictograms accompanying verbal descriptors significantly improve concordance of functional dyspepsia symptom ratings by patients with evaluation by their physicians.

journal_name

Aliment Pharmacol Ther

authors

Tack J,Carbone F,Holvoet L,Vanheel H,Vanuytsel T,Vandenberghe A

doi

10.1111/apt.12855

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

523-30

issue

5

eissn

0269-2813

issn

1365-2036

journal_volume

40

pub_type

杂志文章,随机对照试验
  • Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

    abstract:BACKGROUND:For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. AIM:To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15555

    authors: Sands BE,Armuzzi A,Marshall JK,Lindsay JO,Sandborn WJ,Danese S,Panés J,Bressler B,Colombel JF,Lawendy N,Maller E,Zhang H,Chan G,Salese L,Tsilkos K,Marren A,Su C

    更新日期:2020-01-01 00:00:00

  • A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.

    abstract:BACKGROUND:Ursodeoxycholic acid (UDCA) prolongs transplantation-free survival in primary biliary cirrhosis (PBC). However, the optimal therapeutic dose has not been established. AIM:To compare the effects of UDCA administered in daily doses of 10 vs. 20 mg/kg on symptoms, liver biochemistry and biliary UDCA enrichment...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00395.x

    authors: Van Hoogstraten HJ,De Smet MB,Renooij W,Breed JG,Engels LG,Den Ouden-Muller JW,Rijk MC,Smit AM,Zwertbroek R,Hop WC,van Berge Henegouwen GP,Schalm SW,van Buuren HR

    更新日期:1998-10-01 00:00:00

  • Review article: COVID-19 and liver disease-what we know on 1st May 2020.

    abstract:BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15813

    authors: Garrido I,Liberal R,Macedo G

    更新日期:2020-07-01 00:00:00

  • Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.

    abstract:BACKGROUND:Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM:To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1999.00592.x

    authors: Fabris P,Tositti G,Mazzella G,Zanetti AR,Nicolin R,Pellizzer G,Benedetti P,de Lalla F

    更新日期:1999-09-01 00:00:00

  • Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

    abstract:BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both d...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00806.x

    authors: Geus WP,Mathôt RA,Mulder PG,Lamers CB

    更新日期:2000-08-01 00:00:00

  • Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.

    abstract:BACKGROUND:Gastrimmune is an immunogenic form of gastrin. It raises in situ antibodies against two proliferative forms of gastrin: amidated and glycine-extended gastrin-17. It has been shown to have a therapeutic action in several in vivo tumour models. Following immunization, due to the complex equilibrium that exists...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01081.x

    authors: Smith AM,Morris T,Justin T,Michaeli D,Watson SA

    更新日期:2001-12-01 00:00:00

  • Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study.

    abstract:BACKGROUND:Irritable bowel syndrome is characterised by chronic abdominal pain and frequent comorbid anxiety. The substance P ⁄ neurokinin-1 receptor system is implicated in the regulation of both pain and anxiety, suggesting a potential therapeutic target in IBS. AIM:To determine whether inhibition of the neurokinin-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2011.04958.x

    authors: Tillisch K,Labus J,Nam B,Bueller J,Smith S,Suyenobu B,Siffert J,McKelvy J,Naliboff B,Mayer E

    更新日期:2012-02-01 00:00:00

  • Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease affects 10-35% of the adult population worldwide; there is no consensus on its treatment. Omega-3 fatty acids have proven benefits for hyperlipidaemia and cardiovascular disease, and have recently been suggested as a treatment for non-alcoholic fatty liver disease. AIMS:To ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04230.x

    authors: Masterton GS,Plevris JN,Hayes PC

    更新日期:2010-04-01 00:00:00

  • Lessons from prolonged gastric pH monitoring.

    abstract::Intragastric pH monitoring has shown that the distribution of acidity within the stomach is not homogeneous. Not only is it affected by meals but it also has a circadian rhythm in which nocturnal pH falls to very acid levels in normal subjects. Although results of pH monitoring are highly reproducible within individua...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1987.tb00661.x

    authors: Bumm R,Blum AL,Bauerfeind P,Emde C

    更新日期:1987-01-01 00:00:00

  • Collagen proportionate area predicts clinical outcomes in patients with alcohol-related liver disease.

    abstract:BACKGROUND:No prognostic tools are established for alcohol-related liver disease (ALD). Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies using digital image analysis. AIM:To assess the predictive value of CPA on hepatic decompensation and liver-related morta...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.16111

    authors: Israelsen M,Guerrero Misas M,Koutsoumourakis A,Huang Y,Thiele M,Hall A,Rasmussen D,Covelli C,Buzzetti E,Prat LI,Roccarina D,Detlefsen S,Luong TV,Quaglia A,Krag A,Jeffrey G,Pinzani M,Tsochatzis EA

    更新日期:2020-12-01 00:00:00

  • Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.

    abstract:BACKGROUND:Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM:To assess the effectiveness and safety of OCA...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16181

    authors: Gomez E,Garcia Buey L,Molina E,Casado M,Conde I,Berenguer M,Jorquera F,Simón MA,Olveira A,Hernández-Guerra M,Mesquita M,Presa J,Costa-Moreira P,Macedo G,Arenas JI,Manuel Sousa J,Ampuero J,Morillas RM,Santos A,De Car

    更新日期:2020-12-12 00:00:00

  • Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

    abstract:OBJECTIVE:To determine whether flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol, Zixoryn) is effective in ameliorating pruritus of cholestasis, particularly in primary bilary cirrhosis. METHODS AND RESULTS:50 patients (46 with primary biliary cirrhosis, PBC) took oral flumecinol 600 mg or identical placebo once wee...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00297.x

    authors: Turner IB,Rawlins MD,Wood P,James OF

    更新日期:1994-06-01 00:00:00

  • Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

    abstract:BACKGROUND:Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link. AIM:To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and respons...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03185.x

    authors: Qua CS,Wong CH,Gopala K,Goh KL

    更新日期:2007-02-01 00:00:00

  • Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

    abstract:BACKGROUND:Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. AIM:To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02755.x

    authors: Cardenas VM,Graham DY,El-Zimaity HM,Opekun AR,Campos A,Chavez A,Guerrero L

    更新日期:2006-01-15 00:00:00

  • The prevalence of Helicobacter pylori in peptic ulcer disease.

    abstract::Both duodenal and gastric ulcer disease are closely associated with Helicobacter pylori infection. An infected individual has an estimated lifetime risk of 10-20% for the development of peptic ulcer disease, which is at least 3-4 fold higher than in non-infected subjects. H. pylori infection can be diagnosed in 90-100...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Kuipers EJ,Thijs JC,Festen HP

    更新日期:1995-01-01 00:00:00

  • Personal view: cost and benefit of medical rituals in gastroenterology.

    abstract:BACKGROUND:Unable to resolve a medical problem, gastroenterologists occasionally choose an ineffectual intervention instead. The elusive path to effectual management becomes substituted with an ineffectual but readily available medical ritual. The term 'ritual' refers to the utilization of an ineffectual intervention w...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02252.x

    authors: Sonnenberg A

    更新日期:2004-11-01 00:00:00

  • Review article: intra-oesophageal impedance monitoring for the assessment of bolus transit and gastro-oesophageal reflux.

    abstract:BACKGROUND:Intra-oesophageal impedance monitoring can be used to assess the clearance of a swallowed bolus (oesophageal transit) and to detect gastro-oesophageal reflux independent of its acidity. AIM:To discuss the clinical application of the impedance technique for the assessment of bolus transit and gastro-oesophag...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03863.x

    authors: Conchillo JM,Smout AJ

    更新日期:2009-01-01 00:00:00

  • There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia.

    abstract:BACKGROUND:The relationship between Helicobacter pylori infection and non-ulcer dyspepsia is not established. AIM:To determine whether eradication of H. pylori might be of benefit in non-ulcer dyspepsia patients. METHODS:We randomly assigned 129 H. pylori infected patients with severe epigastric pain, without gastro-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2001.01014.x

    authors: Bruley Des Varannes S,Fléjou JF,Colin R,Zaïm M,Meunier A,Bidaut-Mazel C

    更新日期:2001-08-01 00:00:00

  • Endoscopic sphincterotomy with or without cholecystectomy for choledocholithiasis in high-risk surgical patients: a decision analysis.

    abstract:BACKGROUND:Laparoscopic cholecystectomy (LC) is recommended for patients with choledocholithiasis after ERCP with sphincterotomy (ES) and stone extraction. AIM:We designed a decision model to address whether ES alone versus ES followed by LC (ES + LC) is the optimal treatment in high-risk patients with choledocholithi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03103.x

    authors: Siddiqui AA,Mitroo P,Kowalski T,Loren D

    更新日期:2006-10-01 00:00:00

  • Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial.

    abstract::Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q.d.s.) or ranitidine (150 mg b.d.) for an 8-week period. Upper gastrointe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1993.tb00145.x

    authors: Arvanitakis C,Nikopoułos A,Theoharidis A,Giannoulis E,Vagios I,Anthopoulou H,Michailidis D,Tourkantonis A

    更新日期:1993-12-01 00:00:00

  • Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration.

    abstract:BACKGROUND:Bismuth compounds prevent gastric injury from the short-term administration of nonsteroidal anti-inflammatory drugs. We studied the mechanisms underlying the gastroprotective actions of bismuth subsalicylate against indomethacin-induced injury in rats. METHODS:An in vivo microscopic technique was used in wh...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1997.00170.x

    authors: Tanaka S,Guth PH,Carryl OR,Kaunitz JD

    更新日期:1997-06-01 00:00:00

  • Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Clostridium difficile (C. difficile) infection in hospitals in developed countries continues to be a major public health hazard despite increased control measures including review of antibiotic policies and hygiene measures. Patients with colitis are thought to be particularly vulnerable to C. difficile asso...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04661.x

    authors: Jen MH,Saxena S,Bottle A,Aylin P,Pollok RC

    更新日期:2011-06-01 00:00:00

  • Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs.

    abstract:BACKGROUND:It is not clear whether the incidence or early mortality related to peptic ulcer perforation has changed. AIM:To evaluate the incidence and mortality related to peptic ulcer perforation while considering the intake of low-dose aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS:We recorded t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03808.x

    authors: Taha AS,Angerson WJ,Prasad R,McCloskey C,Gilmour D,Morran CG

    更新日期:2008-10-01 00:00:00

  • Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.

    abstract:BACKGROUND:Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM:A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2008.03884.x

    authors: Quigley EM,Vandeplassche L,Kerstens R,Ausma J

    更新日期:2009-02-01 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract:BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12912

    authors: Dawwas MF,Aithal GP

    更新日期:2014-10-01 00:00:00

  • Childhood coeliac disease: towards an improved serological mass screening strategy.

    abstract:BACKGROUND:In 1997-1998, 6127 asymptomatic children aged 2-4 years were screened for coeliac disease (CD) by anti-endomysium (EmA) testing in the Netherlands. After 6 (+/-2) months, biopsies were performed in 57 seropositive children; 31(54%) had villous atrophy, but 26 (46%), all HLA-DQ2/DQ8 positive, had normal histo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.04226.x

    authors: Hogen Esch CE,Csizmadia GD,van Hoogstraten IM,Schreurs MW,Mearin ML,von Blomberg BM

    更新日期:2010-04-01 00:00:00

  • Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

    abstract::Proton pump inhibitors have dramatically influenced the management of acid-peptic disorders in recent years. They all have a broadly similar mechanism of action and are extensively metabolized in the liver via cytochromes P450 2C19 and 3A4. There is some variation in their potential for drug interactions due to differ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00788.x

    authors: Stedman CA,Barclay ML

    更新日期:2000-08-01 00:00:00

  • Review article: systemic treatment of hepatocellular carcinoma.

    abstract:BACKGROUND:The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the first- and second-lin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.14913

    authors: Pinter M,Peck-Radosavljevic M

    更新日期:2018-09-01 00:00:00

  • Indomethacin-induced gastric antral damage in hamsters: are neutrophils involved?

    abstract:BACKGROUND:A direct role for neutrophils in the pathophysiology of indomethacin-induced gastric damage is controversial. Therefore, such damage was evaluated in hamsters. METHODS:Gastric antral damage was evaluated 4 h after the oro-gastric administration of indomethacin (30 mg/kg). Prior to indomethacin, hamsters wer...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00444.x

    authors: Fitzpatrick LR,Sakurai K,Le T

    更新日期:1999-02-01 00:00:00

  • New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.

    abstract:BACKGROUND:Anti-tumour necrosis factor α (anti-TNF) agents have been implicated in drug-induced liver injury. There is minimal data on this occurrence in inflammatory bowel disease (IBD) patients. AIM:To identify the characteristics of liver enzyme elevations following anti-TNF therapy initiation in IBD. METHODS:A re...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13159

    authors: Shelton E,Chaudrey K,Sauk J,Khalili H,Masia R,Nguyen DD,Yajnik V,Ananthakrishnan AN

    更新日期:2015-05-01 00:00:00